YS-035 hydrochlorideInhibits K+ outward/pacemaker current CAS# 89805-39-0 |
2D Structure
- gamma-secretase modulator 2
Catalog No.:BCC1584
CAS No.:1093978-89-2
- BMS-708163 (Avagacestat)
Catalog No.:BCC2104
CAS No.:1146699-66-2
- Calcifediol
Catalog No.:BCC4949
CAS No.:19356-17-3
- DAPT (GSI-IX)
Catalog No.:BCC3618
CAS No.:208255-80-5
- (24S)-24,25-Dihydroxyvitamin D3
Catalog No.:BCC1290
CAS No.:55700-58-8
- Begacestat
Catalog No.:BCC2346
CAS No.:769169-27-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 89805-39-0 | SDF | Download SDF |
PubChem ID | 6917841 | Appearance | Powder |
Formula | C21H30ClNO4 | M.Wt | 395.93 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | 2-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylethanamine;hydrochloride | ||
SMILES | CN(CCC1=CC(=C(C=C1)OC)OC)CCC2=CC(=C(C=C2)OC)OC.Cl | ||
Standard InChIKey | GYBONEHHSUABAO-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C21H29NO4.ClH/c1-22(12-10-16-6-8-18(23-2)20(14-16)25-4)13-11-17-7-9-19(24-3)21(15-17)26-5;/h6-9,14-15H,10-13H2,1-5H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | A Ca2+ blocker that strikingly prolongs cardiac action potentials by inhibiting pacemaker current and K+ outward currents. |
YS-035 hydrochloride Dilution Calculator
YS-035 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5257 mL | 12.6285 mL | 25.257 mL | 50.514 mL | 63.1425 mL |
5 mM | 0.5051 mL | 2.5257 mL | 5.0514 mL | 10.1028 mL | 12.6285 mL |
10 mM | 0.2526 mL | 1.2628 mL | 2.5257 mL | 5.0514 mL | 6.3142 mL |
50 mM | 0.0505 mL | 0.2526 mL | 0.5051 mL | 1.0103 mL | 1.2628 mL |
100 mM | 0.0253 mL | 0.1263 mL | 0.2526 mL | 0.5051 mL | 0.6314 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- PF-3758309
Catalog No.:BCC1853
CAS No.:898044-15-0
- 5-Ethyltio-1H-Tetrazole
Catalog No.:BCC2844
CAS No.:89797-68-2
- Aceclofenac
Catalog No.:BCC5233
CAS No.:89796-99-6
- Myrianthic acid
Catalog No.:BCN7130
CAS No.:89786-84-5
- 2,3,24-Trihydroxy-12-ursen-28-oic acid
Catalog No.:BCN1314
CAS No.:89786-83-4
- Tazobactam acid
Catalog No.:BCC9160
CAS No.:89786-04-9
- Toremifene Citrate
Catalog No.:BCC4487
CAS No.:89778-27-8
- Toremifene
Catalog No.:BCC2010
CAS No.:89778-26-7
- AST-1306
Catalog No.:BCC3727
CAS No.:897383-62-9
- 7-O-Acetyl-4-O-demethylpolysyphorin
Catalog No.:BCN3984
CAS No.:89706-39-8
- KX2-391
Catalog No.:BCC5080
CAS No.:897016-82-9
- Androstadienedione
Catalog No.:BCC8824
CAS No.:897-06-3
- Esculentoside D
Catalog No.:BCN5013
CAS No.:89808-50-4
- XL228
Catalog No.:BCC2058
CAS No.:898280-07-4
- 4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one hydrochloride
Catalog No.:BCC8647
CAS No.:898543-06-1
- 3-Epichromolaenide
Catalog No.:BCN7241
CAS No.:89913-53-1
- 3-O-Acetyl-alpha-boswellic acid
Catalog No.:BCN2671
CAS No.:89913-60-0
- Beta-Carboline-1-propanoic acid
Catalog No.:BCN5805
CAS No.:89915-39-9
- Gymnoside III
Catalog No.:BCN8218
CAS No.:899430-03-6
- A 438079 hydrochloride
Catalog No.:BCC1317
CAS No.:899431-18-6
- Platycoside K
Catalog No.:BCN3242
CAS No.:899447-64-4
- A 438079
Catalog No.:BCC1316
CAS No.:899507-36-9
- ML 348
Catalog No.:BCC5611
CAS No.:899713-86-1
- CC-930
Catalog No.:BCC1459
CAS No.:899805-25-5
Inhibition of potassium outward currents and pacemaker current in sheep cardiac Purkinje fibres by the verapamil derivative YS 035.[Pubmed:1775198]
Naunyn Schmiedebergs Arch Pharmacol. 1991 Dec;344(6):653-61.
The electrophysiologic mode of action and potency of the verapamil derivative YS 035 (N,N-bis-(3,4-dimethoxyphenethyl)-N-methyl amine) were investigated in sheep cardiac Purkinje fibres. Action potential duration measured at a repolarization level of -60 mV (APD-60) and membrane currents recorded with the two-microelectrode voltage-clamp technique were evaluated. At 10 mumols/l YS 035 APD-60 was increased to about 115% of reference. Prolongation measured as percentage of the respective control exhibited on the average no dependence on stimulation frequency (0.17-2 Hz). At 100 mumols/l membrane became depolarized to about -50 mV and action potentials could no longer be elicited. Further study was focussed on effects on outward currents, mostly activated at a frequency of 0.05 Hz. Transient outward current (ito) was completely blocked at 100 mumols/l and half-maximal inhibition occurred at about 14 mumols/l. Inwardly rectifying potassium current (ik1) was reduced to 47% of reference at 100 mumols/l. An initially activating outward current at positive membrane potentials (iinst) was reduced to 73% at 100 mumols/l. Time-dependent (delayed) outward current (iK) was on the average not affected up to 100 mumols/l. Besides inhibition of repolarizing outward currents YS 035 completely blocked pacemaker current (if) at 100 mumols/l and half-maximal reduction was achieved at 5 mumols/l. YS 035 (1-100 mumols/l) did not clearly affect time constants of activation at selected test potentials (IK: +35 mV; if: -90 mV) or inactivation (ito: 0 mV). Voltage-dependent control mechanisms of currents (ito, if) were not influenced by YS 035 but the amount of available current was reduced.(ABSTRACT TRUNCATED AT 250 WORDS)
Properties of a new calcium ion antagonist on cellular uptake and mitochondrial efflux of calcium ions.[Pubmed:6721841]
Biochem J. 1984 Mar 15;218(3):899-905.
Compound YS 035 [NN-bis-(3,4-dimethoxyphenethyl)-N-methylamine] is a new synthetic compound capable of inhibiting Ca2+ uptake by different cells. The inhibition of Ca2+ uptake by muscle cells isolated from chicken embryo is dose-dependent in the compound YS 035 concentration range 10-30 microM. The new compound also inhibits Ca2+ entry into rat brain synaptosomes and less effectively into baby-hamster kidney cells. Compound YS 035 partially inhibits the slow Ca2+ release induced by Ruthenium Red and the rapid Na+-dependent efflux from heart mitochondria. The inhibition of the Na+/Ca2+ exchange appears to be of a non-competitive type with an apparent Ki of 28 microM. The new Ca2+ antagonist totally inhibits the Ca2+ efflux from liver mitochondria induced by Ruthenium Red, but it does not affect the release induced by uncoupler, respiratory inhibitor or chelator, nor the mitochondrial ATP synthesis and membrane potential. The properties shown by the new compound indicate it to be a Ca2+ antagonist and a useful tool for studies on the mitochondrial Ca2+ transport.